Imagine a cancer treatment designed for one person only, built from the unique genetic fingerprint of their tumour. This is the frontier of personalised medicine, and Hyderabad-based startup PopVax is joining the global race to make it a reality.
The 'Wanted Poster' for Your Cancer
Personalised
cancer vaccines are a revolutionary form of immunotherapy. Unlike preventative vaccines for diseases like the flu, these are therapeutic treatments for people who already have cancer. The process starts by taking a sample of a patient's tumour and sequencing its genetic code. Cancer cells have genetic changes, or mutations, that healthy cells don't. These mutations can create unique markers on the surface of cancer cells called 'neoantigens'. Because no two tumours have the exact same mutations, these neoantigens are highly specific to an individual's cancer. The vaccine is then designed to teach the patient’s immune system to recognise these specific markers—like showing it a custom 'wanted poster'—so it can hunt down and destroy any cancer cells carrying them. This high level of precision promises a more targeted attack on cancer, potentially avoiding the collateral damage to healthy cells often caused by chemotherapy.
Hyderabad's PopVax Enters the Fray
At the heart of this effort in India is PopVax, a Hyderabad-based biotech company founded in 2021 by Soham Sankaran. The company is leveraging the same messenger RNA (mRNA) technology that became famous during the COVID-19 pandemic. PopVax uses artificial intelligence and machine learning to analyse a tumour's genetic data and predict which neoantigens will provoke the strongest immune response. These chosen targets are then encoded into an mRNA vaccine. When administered, the mRNA instructs the patient's own cells to produce these neoantigen proteins, training the immune system to recognise and fight the cancer. To accelerate this work, PopVax recently launched the 'RNA Foundry' in Hyderabad, an integrated facility for research, development, and manufacturing of these bespoke vaccines.
The Hurdle of 'Clinically Unproven'
While the science is exciting, the headline's crucial caveat is that the clinical effectiveness of this approach is 'still unproven'. This means that while the theory is sound and early results from international studies are promising, these personalised vaccines have not yet passed the large-scale, rigorous human clinical trials required for regulatory approval as a standard treatment. Globally, some personalised vaccines, often combined with other immunotherapies, have shown success in keeping cancer from recurring in small trials for diseases like melanoma and pancreatic cancer. However, developing new medical treatments is a long and difficult road. PopVax's cancer candidates have not yet been administered to patients. The company plans to begin with compassionate-use cases for a small number of patients outside India, which will provide early data to guide future clinical trials. These are essential first steps before the treatment can be considered safe and effective for wider use.
Why This Matters for Indian Biotech
PopVax's ambition is a significant milestone for India's burgeoning biotechnology ecosystem. The company, which started in a small shared lab and now employs over 100 scientists, is backed by prominent global investors including the Gates Foundation, Ethereum co-founder Vitalik Buterin, and the US government agency BARDA. By building capabilities in cutting-edge fields like mRNA technology and generative AI for protein design, PopVax is positioning India as a player in a highly advanced scientific field. The firm has already developed a fridge-stable COVID-19 vaccine candidate, which has entered clinical trials and showcases its platform's potential for stability—a key advantage for distribution. Success in the complex field of personalised oncology could further cement India's reputation beyond being the 'pharmacy of the world' for generics and into a hub for novel, first-in-class drug innovation.
